BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
详细信息 查看全文
- 作者：Hengrui Zhu1 ; Fee Bengsch1 ; Nikolaos Svoronos2 ; Melanie R. Rutkowski2 ; Benjamin G. Bitler1 ; Michael J. Allegrezza2 ; Yuhki Yokoyama1 ; Andrew V. Kossenkov3 ; James E. Bradner4 ; Jose R. Conejo-Garcia2 ; jrconejo@wistar.org" class="auth_mail" title="E-mail the corresponding author ; Rugang Zhang1 ; 5 ; rzhang@wistar.org" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：13 September 2016
- 年：2016
- 卷：16
- 期：11
- 页码：2829-2837
- 全文大小：2792 K
文摘
- •
BET inhibitors suppress PD-L1 expression in both immune cells and tumor cells
- •
CD274 is a direct target gene of BRD4
- •
BET inhibitors increase cytotoxic T cell activity to limit tumor progression in mice